alpha-asarone and Cardiovascular-Diseases

alpha-asarone has been researched along with Cardiovascular-Diseases* in 2 studies

Reviews

2 review(s) available for alpha-asarone and Cardiovascular-Diseases

ArticleYear
Is it safe to use Acorus calamus as a source of promising bioactive compounds in prevention and treatment of cardiovascular diseases?
    Chemico-biological interactions, 2018, Feb-01, Volume: 281

    Acorus calamus has a rich history in natural medicine, and offers many health benefits. The plant has anti-inflammatory, antimicrobial, diuretic, antiurolithiatic and other properties. Moreover, various parts, especially the rhizome and roots, are sources of a range of bioactive phenolic compounds with beneficial effects on the cardiovascular system. This review article summarizes the current knowledge of the chemical composition of different parts of A. calamus and their roles in the prevention and treatment of cardiovascular diseases. However, as no human studies have been performed, the review only includes in vitro and animal studies. The paper also briefly reviews the toxicity of A. calamus and its products for human health, especially regarding the cardiovascular system.

    Topics: Acorus; Allylbenzene Derivatives; Animals; Anisoles; Body Weight; Cardiovascular Diseases; Epoxy Compounds; Humans; Hypolipidemic Agents; Oils, Volatile; Phenols

2018
Inhibitors of HMG-CoA Reductase: Current and Future Prospects.
    Mini reviews in medicinal chemistry, 2009, Volume: 9, Issue:11

    High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.

    Topics: Allylbenzene Derivatives; Anisoles; Anticholesteremic Agents; Binding Sites; Cardiovascular Diseases; Cholesterol; Databases, Protein; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Structure-Activity Relationship

2009